Keymed Biosciences (FRA:64Z) ROCE % : -21.37% (As of Dec. 2023)

View and export this data going back to 2022. Start your Free Trial

What is Keymed Biosciences ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Keymed Biosciences's annualized ROCE % for the quarter that ended in Dec. 2023 was -21.37%.

Keymed Biosciences ROCE % Historical Data

The historical data trend for Keymed Biosciences's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Keymed Biosciences ROCE % Chart

Keymed Biosciences Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

-27.57

-153.40

-183.56

-7.90

-9.27

Keymed Biosciences Semi-Annual Data
	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
ROCE %	Get a 7-Day Free Trial				-21.12	0.21	-16.02	3.04	-21.37

Keymed Biosciences ROCE % Calculation

Keymed Biosciences's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-43.528	/	( ( (532.454 - 51.413)	+	(498.675 - 40.349) )	/ 2 )
	=	-43.528	/	( (481.041	+	458.326)	/ 2 )
	=	-43.528	/	469.6835
	=	-9.27 %

Keymed Biosciences's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	-101.82	/	( ( (524.271 - 29.509)	+	(498.675 - 40.349) )	/ 2 )
	=	-101.82	/	( ( 494.762	+	458.326 )	/ 2 )
	=	-101.82	/	476.544
	=	-21.37 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2023) EBIT data.

Keymed Biosciences (FRA:64Z) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Keymed Biosciences ROCE % Related Terms

Thank you for viewing the detailed overview of Keymed Biosciences's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Keymed Biosciences (FRA:64Z) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Keymed Biosciences Inc (FRA:64Z) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

02162:Hong Kong

Address

No. 18 BioTown Middle Road, Building D2, Tianfu International BioTown, Chengdu, Sichuan, CHN, 610219

Website

https://www.keymedbio.com

Keymed Biosciences Inc is a biotechnology company with multiple clinical-stage assets. The company is focused on the in-house discovery and development of innovative biological therapies that address large underserved medical needs in the autoimmune and oncology therapeutic areas. The Group is engaged in biopharmaceutical research and development, which is regarded as a single reportable segment. Geographically, it operates in Hong Kong & Mainland China, out of which the majority is from Mainland China.

Keymed Biosciences (FRA:64Z) Headlines

No Headlines